Royalty Pharma plc (NASDAQ:RPRX – Get Rating) CFO Terrance P. Coyne sold 30,000 shares of the firm’s stock in a transaction dated Monday, August 1st. The stock was sold at an average price of $43.19, for a total transaction of $1,295,700.00. Following the transaction, the chief financial officer now directly owns 970,000 shares of the company’s stock, valued at $41,894,300. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.
Royalty Pharma Price Performance
NASDAQ RPRX opened at $42.45 on Friday. The company has a quick ratio of 21.95, a current ratio of 21.95 and a debt-to-equity ratio of 0.70. Royalty Pharma plc has a 12-month low of $34.86 and a 12-month high of $44.75. The company has a market capitalization of $25.77 billion, a PE ratio of 42.45, a price-to-earnings-growth ratio of 1.15 and a beta of 0.28. The firm’s 50 day moving average is $41.87 and its 200-day moving average is $40.68.
Royalty Pharma (NASDAQ:RPRX – Get Rating) last posted its quarterly earnings data on Thursday, May 5th. The biopharmaceutical company reported $0.61 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.72 by ($0.11). Royalty Pharma had a net margin of 26.46% and a return on equity of 16.75%. The business had revenue of $605.00 million during the quarter, compared to analyst estimates of $583.77 million. Equities research analysts anticipate that Royalty Pharma plc will post 2.91 earnings per share for the current fiscal year.
Royalty Pharma Announces Dividend
Analyst Upgrades and Downgrades
A number of equities research analysts recently issued reports on RPRX shares. The Goldman Sachs Group started coverage on shares of Royalty Pharma in a research report on Wednesday, April 27th. They set a “buy” rating and a $56.00 target price for the company. Tigress Financial lifted their price target on shares of Royalty Pharma from $52.00 to $57.00 and gave the stock a “buy” rating in a research report on Thursday, July 14th. JPMorgan Chase & Co. upgraded shares of Royalty Pharma from a “neutral” rating to an “overweight” rating and set a $50.00 price target for the company in a research report on Thursday, April 14th. They noted that the move was a valuation call. UBS Group assumed coverage on shares of Royalty Pharma in a research note on Monday, June 13th. They set a “buy” rating and a $47.00 price objective on the stock. Finally, Citigroup lifted their price objective on shares of Royalty Pharma from $50.00 to $60.00 in a research note on Thursday, July 28th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, Royalty Pharma presently has a consensus rating of “Moderate Buy” and an average price target of $53.00.
Institutional Trading of Royalty Pharma
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Signaturefd LLC raised its holdings in shares of Royalty Pharma by 53.9% in the first quarter. Signaturefd LLC now owns 688 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 241 shares during the last quarter. Aurora Investment Counsel increased its holdings in Royalty Pharma by 0.9% during the first quarter. Aurora Investment Counsel now owns 29,939 shares of the biopharmaceutical company’s stock worth $1,166,000 after buying an additional 257 shares during the last quarter. Humankind Investments LLC increased its holdings in Royalty Pharma by 4.6% during the fourth quarter. Humankind Investments LLC now owns 6,122 shares of the biopharmaceutical company’s stock worth $244,000 after buying an additional 269 shares during the last quarter. Gulf International Bank UK Ltd increased its holdings in Royalty Pharma by 0.5% during the first quarter. Gulf International Bank UK Ltd now owns 57,580 shares of the biopharmaceutical company’s stock worth $2,243,000 after buying an additional 300 shares during the last quarter. Finally, Advisor Group Holdings Inc. increased its holdings in Royalty Pharma by 9.4% during the first quarter. Advisor Group Holdings Inc. now owns 4,265 shares of the biopharmaceutical company’s stock worth $151,000 after buying an additional 366 shares during the last quarter. 51.68% of the stock is currently owned by institutional investors and hedge funds.
About Royalty Pharma
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.
- Get a free copy of the StockNews.com research report on Royalty Pharma (RPRX)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
- Why Apple Could Be At All-Time Highs By Year End
Receive News & Ratings for Royalty Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Royalty Pharma and related companies with MarketBeat.com's FREE daily email newsletter.